Dry Age-Related Macular Degeneration Market: Market Dynamics and Future Trends 2024-2032
The Dry Age-Related Macular Degeneration Market was valued at USD 9.51 billion in 2023 and is projected to reach USD 15.49 billion by 2031, growing at a CAGR of 6.3% during the forecast period.
The Dry Age-Related Macular Degeneration Market was valued at USD 9.51 billion in 2023 and is projected to reach USD 15.49 billion by 2031, growing at a CAGR of 6.3% during the forecast period. This market is driven by a growing aging population, increasing awareness of eye health, and advancements in treatment technologies for age-related eye disorders.
Dry Age-Related Macular Degeneration market size continues to expand due to a rise in age-related vision impairment and increased healthcare expenditure. With innovations in diagnostic imaging and the development of novel therapeutics, the industry is witnessing accelerated momentum globally. Regions with aging demographics, particularly in North America and Europe, are fueling the demand for effective treatment solutions.
Get Free Sample Report @ https://www.snsinsider.com/sample-request/2627
Key Players in the Dry Age-Related Macular Degeneration Market
- Bayer AG
- Pfizer Inc.
- Amgen Inc.
- Biogen
- Novartis AG
- F. Hoffmann-La Roche Ltd
- Samsung Bioepis
- Bausch Health Companies Inc.
- Regeneron Pharmaceuticals Inc.
- Santen Pharmaceuticals Inc.
- Allergan plc
- Alimera Sciences Inc.
- Phio Pharmaceuticals Corp
- Iveric Bio
- Belite Bio Inc.
Key Highlights:
- Market size expected to reach USD 15.49 billion by 2031
- CAGR of 6.3% from 2024 to 2031
- Growth driven by increased prevalence of AMD in the elderly population
- Advancements in pharmaceutical R&D and early diagnosis technologies
- Strategic partnerships and clinical trials by leading players
- Rising awareness of eye care and routine eye checkups
- North America holds the dominant market share, followed by Europe and Asia-Pacific
Future Scope:
The future of the dry age-related macular degeneration market looks promising, with pharmaceutical companies investing heavily in developing new biologics and gene therapies aimed at halting or reversing the progression of AMD. Additionally, AI-powered diagnostic tools are likely to improve early detection, making treatment more effective. Personalized medicine and patient-specific treatment plans are anticipated to become more common, leading to improved outcomes and increased market penetration in emerging economies.
Conclusion:
The dry age-related macular degeneration market is positioned for substantial growth over the next decade, supported by technological progress, aging global populations, and increased public awareness. With continued innovation and strategic collaboration, the market is expected to offer better treatment options, significantly improving the quality of life for patients affected by this condition.
Contact Us: Jagney Dave - Vice President of Client Engagement Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)
Other Related Reports: